Sanofi mulls the sale of certain drugs

|About: Sanofi (SNY)|By:, SA News Editor

Reuters reports that the French pharmaceutical firm (SNY) is working with Evercore partners to find a buyer for a portfolio of mature drugs that include treatments for high blood pressure and cardio-metabolic diseases.

The businesses, which generate ~$3.7B in annual sales, should fetch between $7B and $8B.

Generic firms or specialty pharma companies are likely acquirers.

Sanofi's initiative is consistent with other members of big pharma who want to shed smaller, less profitable and/or non-core businesses in order to focus on their principal growth drivers.